New York Pharma Forum elects new president
This article was originally published in Scrip
The New York Pharma Forum, a US association of biopharmaceutical companies with a focus on Japan, has elected Dr Sapan Shah as president, effective immediately. Dr Shah, who is president and CEO of Shionogi's US subsidiary and was formerly vice-president of the forum, succeeds Dr Kenji Arima of Asubio Pharmaceuticals in the US, who is returning to Japan. The non-profit group organises networking and educational events on various issues for industry and other members and was set up around 20 years ago.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.